Romark Global Pharma expanding Puerto Rico operations with $80 million investment
To manufacture Alinia, NT-300, a new drug to treat cold, influenza A and B, rhinoviruses and other enteroviruses
SAN JUAN – Tampa, Florida-based Romark Global Pharma LLC is investing $80 million in the expansion of its facilities in Manatí, Puerto Rico, creating 200 jobs.
The pharmaceutical company, which develops small molecules for treating infectious diseases and cancer as well as providing antiviral drugs, also has facilities in Australia, Luxembourg and Belgium. It established its presence in Puerto Rico in 2014, when it announced the investment of $110 million and the creation of 200 jobs in Manatí.
The expansion will allow the company to manufacture Alinia and NT-300, a new investigational drug for the treatment of cold and flu due to influenza A and B viruses, rhinoviruses and other enteroviruses.
Puerto Rico Economic Development Secretary Manuel Laboy Rivera said the government granted the company $2.5 million in incentives for its job creation and its expenses related to infrastructure construction, transportation and installation of manufacturing equipment.
In August 2018, Romark acquired the assets of Scienza Labs in Dorado, which affords it analytical laboratory support for the Manatí operation, as well as other research and development activities that it conducts.